Feedback / Questions
AO-252 - A2A Pharma, OncoCube Therap
https://www.prnewswire.com/news-releases/a2a-pharmaceuticals-inc-announces-phase-1-clinical-trial-advancements-in-tacc3-inhibition-program-targeting-multiple-cancers-302329584.html
Dec 11, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next